EGFR and cancer: Another molecular aspect considered vital in this network is EGFR tyrosine kinase inhibitor resistance.[43] EGFR is a transmembrane receptor tyrosine kinase that functions as a crucial component of cell signaling pathways.[44] Clinically, tyrosine kinase inhibitors are used to treat cancers having EGFR mutations or their aberrant activation.[45] Because EGFR mutations are known to induce drug resistance, researchers have used miRNAs to treat cancers displaying resistance toward EGFR– tyrosine kinase inhibitors.[46]